As per MRFR analysis, the China Non-Alcoholic Steatohepatitis Biomarkers Market Size was estimated at 8.4 (USD Million) in 2023. The China Non-Alcoholic Steatohepatitis Biomarkers Market Industry is expected to grow from 10.5 (USD Million) in 2024 to 140.4 (USD Million) by 2035. The China Non-Alcoholic Steatohepatitis Biomarkers Market CAGR (growth rate) is expected to be around 26.584% during the forecast period (2025 - 2035).
The China Non-Alcoholic Steatohepatitis (NASH) Biomarkers Market is seeing significant trends shaped by the country's rising healthcare challenges associated with liver diseases. The increase in obesity and diabetes prevalence in China is a key market driver, resulting in a growing demand for effective diagnostic tools and treatment options for non-alcoholic fatty liver disease (NAFLD) and its more severe form, NASH.
As the Chinese government emphasizes the importance of public health, many healthcare initiatives are increasingly focusing on the recognition and management of liver diseases, further propelling market growth. Recent trends indicate an increased investment in research and development within the Chinese biotech sector to discover novel biomarkers for NASH.
This focus not only aims to improve diagnostic accuracy but also seeks to support the development of targeted therapies. The rise of personalized medicine is also relevant, as healthcare providers and patients look for tailored treatment solutions based on specific biomarker profiles.
Additionally, collaborations between universities, research institutions, and pharmaceutical companies are becoming more common, helping to advance biomarker research and streamline clinical trials in China. The rising awareness of liver health among the general population provides ample opportunities for companies operating in this market.
Patient education campaigns and initiatives by the government and private organizations can further elevate understanding of NASH and the importance of early detection. Digital health technologies, including telemedicine and mobile applications, also present avenues for enhancing patient engagement in monitoring liver health.
As more people become aware of NASH, the increasing demand for non-invasive biomarkers within China's healthcare system is expected to grow, creating a dynamic environment for innovative solutions in this field.
Source: Primary Research, Secondary Research, MRFR Database and Analyst Review
According to research, the prevalence of Non-Alcoholic Fatty Liver Disease (NAFLD) has significantly increased in China, where liver steatosis has been seen in about 29.6% of adults in recent years. This rise is mostly attributable to changes in lifestyle, including sedentary activity and poor eating, which fuel obesity and associated metabolic disorders.
According to the Chinese National Health Commission, the rising prevalence of fatty liver disease is an urgent public health issue that has to be addressed by healthcare officials. As a result, the China Non-Alcoholic Steatohepatitis Biomarkers Market Industry is anticipated to see a sharp increase in demand for biomarkers to diagnose Non-Alcoholic Steatohepatitis (NASH) and track its development.
More screening programs are expected as awareness grows, which will further fuel market expansion.
The China Non-Alcoholic Steatohepatitis Biomarkers Market is poised for growth due to substantial advancements in biomarker development. Chinese-based pharmaceutical companies and research institutes are actively engaged in innovative Research and Development (R&D) to identify more sensitive and specific biomarkers for NASH.
For instance, recent technological progress has led to the establishment of non-invasive biomarkers that effectively differentiate between NAFLD and NASH. According to the Chinese Society of Hepatology, collaboration between industry players and academic institutions has accelerated the pace of biomarker discovery, with several patents filed that underline the innovative efforts in this domain.
This advancement not only boosts diagnostic capabilities but also encourages therapeutic development, resulting in a vibrant market landscape.
The government of China is actively implementing policies aimed at addressing liver diseases and enhancing public health. Initiatives such as the Healthy China 2030 plan specifically target improving liver health among its citizens by promoting awareness about metabolic diseases, including Non-Alcoholic Steatohepatitis (NASH).
Strengthened regulatory frameworks and funding for research can lead to increased investments in the China Non-Alcoholic Steatohepatitis Biomarkers Market Industry. Furthermore, government support through grants and collaborations with healthcare organizations will likely facilitate the advancement of diagnostic tools, with an emphasis on early detection and prevention strategies for NASH.
The growing focus on preventive healthcare can significantly expand the potential for market growth.
The China Non-Alcoholic Steatohepatitis Biomarkers Market is structured into several essential types that play pivotal roles in the management and understanding of this liver condition. Hepatic Fibrosis Biomarkers are particularly significant as they assist in evaluating the extent of fibrosis in patients with non-alcoholic steatohepatitis (NASH), which is crucial for determining the disease's stage and treatment options.
The demand for effective diagnostic tools is rising, given China's increasing prevalence of liver diseases attributed to lifestyle changes and diet, thus making this segment vital for patient management in clinical settings. Serum Biomarkers represent another critical type within the market, as they are among the first-line diagnostics used to detect changes in liver metabolism and injury.
These biomarkers derive from blood tests and help in both screening and monitoring the progression of non-alcoholic steatohepatitis. The ongoing advancements in technology and diagnostic tools contribute to the growth of this segment, particularly in urban areas where health awareness is elevating.
Oxidative Stress Biomarkers are gaining traction within the market due to their connection with the inflammatory processes related to NASH. These biomarkers serve as indicators of cellular damage and inflammation, providing insights that can guide therapeutic decisions.
The increasing focus on personalized medicine in China amplifies the relevance of this segment, as healthcare providers seek to tailor treatments based on individual oxidative stress profiles. Apoptosis Biomarkers also offer unique insights into the pathogenesis of NASH.
They aid in understanding the mechanisms leading to cell death in liver tissues, revealing opportunities for targeted therapies. As research progresses, the potential for innovative treatments based on apoptosis regulation is likely to enhance the significance of this category within the market.
Lastly, while the "Others" segment encompasses additional emerging biomarkers that do not neatly fit into the previous classifications, its growth reflects the diverse and evolving landscape of biomarker discovery. As research advances in metabolic diseases, this category is likely to include new and promising candidates that could improve diagnostic accuracy and patient management.
In the context of China, where liver-related diseases are on the rise, the growth of the China Non-Alcoholic Steatohepatitis Biomarkers Market can be attributed to increased screening efforts, the adoption of advanced biomedical technologies, and a deeper understanding of these types.
This comprehensive approach not only addresses the challenges posed by rising NASH cases but also offers substantial opportunities for stakeholders in the healthcare sector looking to innovate and provide solutions tailored to the specific needs of the Chinese population.
Source: Primary Research, Secondary Research, MRFR Database and Analyst Review
Non-Alcoholic Steatohepatitis Biomarkers Market End User Insights
The End User segment of the China Non-Alcoholic Steatohepatitis Biomarkers Market is characterized by a diverse range of entities, including Research Institutes and Academics, Diagnostic Centres, Pharmaceutical Companies and Contract Research Organizations, Hospitals and Clinics, as well as Others. Research Institutes and Academics play a pivotal role in enhancing understanding and the development of innovative biomarkers, fostering advancements in diagnostic techniques.
Diagnostic Centres are crucial as they provide essential testing services, allowing healthcare providers to identify and monitor Non-Alcoholic Steatohepatitis effectively. Pharmaceutical Companies and Contract Research Organizations are instrumental in research and development initiatives, significantly contributing to the validation of biomarkers and the discovery of therapeutic solutions.
Hospitals and Clinics offer comprehensive patient care, addressing clinical needs through biomarker utilization in diagnostic and management protocols. The combined efforts of these entities not invigorating only enhance the China Non-Alcoholic Steatohepatitis Biomarkers Market revenue but also drive advancements in the overall healthcare framework in the region.
Additionally, the growing prevalence of Non-Alcoholic Steatohepatitis cases in China further underscores the importance and demand for effective biomarkers across these diverse End User categories.
The China Non-Alcoholic Steatohepatitis Biomarkers Market is experiencing significant growth, driven by an increased prevalence of metabolic disorders, heightened awareness regarding liver health, and advancements in biomarker research. As the market evolves, competition is intensifying among prominent players who are leveraging innovative technologies and strategic partnerships to develop novel biomarkers for effective diagnosis and management of non-alcoholic steatohepatitis (NASH).
The landscape features a mix of established pharmaceutical companies and emerging biotechnology firms dedicated to enhancing diagnostic capabilities, fostering collaborations with academic institutions, and pursuing regulatory approvals in a bid to capture a larger market share.
This influx of innovation not only enhances clinical outcomes but also contributes to a more profound understanding of the underlying pathophysiology of NASH, opening new avenues for therapeutic interventions. In this competitive landscape, Novartis stands out due to its robust market presence and strategic initiatives tailored specifically for the China Non-Alcoholic Steatohepatitis Biomarkers Market.
The company is known for its commitment to research and development, focusing on novel biomarkers that underpin the diagnosis and management of NASH. Novartis has built strong relationships with key opinion leaders in China to ensure the successful deployment of its products.
The firm's extensive pipeline, combined with its expertise in liver diseases, positions Novartis as a formidable competitor. Additionally, the company’s established distribution networks and collaborations with local healthcare providers enhance its ability to penetrate the market effectively, ensuring that its innovative solutions reach a broad patient population.
Furthermore, Novartis emphasizes educational initiatives to promote awareness of NASH, further reinforcing its commitment to improving liver health in China. Intercept Pharmaceuticals, on the other hand, is also making notable strides within the China Non-Alcoholic Steatohepatitis Biomarkers Market by focusing on the introduction of targeted therapies and biomarkers aimed at diagnosing and monitoring liver diseases.
The company specializes in developing treatments that address NASH and has cultivated a deep understanding of the Chinese healthcare environment. Intercept Pharmaceuticals is characterized by its unique product portfolio, which includes advanced biomarkers that can identify patients at risk for NASH complications.
The company’s strength lies in its innovative research approach and strategic collaborations with local biotech firms, which bolster its market presence and allow for localized development of its products. Additionally, mergers and acquisitions have enhanced Intercept Pharmaceuticals’ operational capabilities in China, enabling it to navigate regulatory complexities more effectively.
Its focused strategy on enhancing patient outcomes through tailored biomarker solutions holds promise for key growth as it aims to expand its influence within the Chinese market for non-alcoholic steatohepatitis.
The China Non-Alcoholic Steatohepatitis Biomarkers Market has seen notable developments recently, particularly with companies like Novartis and Intercept Pharmaceuticals accelerating their Research and Development efforts to enhance diagnostic capabilities and treatment options for Non-Alcoholic Steatohepatitis (NASH). In September 2023, Gilead Sciences announced advancements in their biomarker assays, contributing to a growing focus on precision medicine in this field.
Meanwhile, Mirum Pharmaceuticals has initiated collaborative studies with Duke University to explore novel biomarkers that can expedite NASH diagnosis. Furthermore, Guangzhou Medicines Corporation and Wuxi AppTec have been actively pursuing strategic partnerships aimed at expanding their biomarker portfolios.
In August 2023, Boehringer Ingelheim confirmed its acquisition of a key technology platform designed for NASH therapies, demonstrating a proactive approach toward securing a leading position in the market. The overall growth in valuation for these companies reflects a positive outlook, anticipating a surge in the demand for biomarkers as public awareness of NASH increases.
Over the last two years, particularly from 2021 to 2023, the market has experienced rapid evolution, attributed to rising obesity rates and awareness initiatives in China, with government support facilitating innovation in NASH biotechnology.
| Report Attribute/Metric Source: | Details |
| MARKET SIZE 2023 | 8.4(USD Million) |
| MARKET SIZE 2024 | 10.5(USD Million) |
| MARKET SIZE 2035 | 140.4(USD Million) |
| COMPOUND ANNUAL GROWTH RATE (CAGR) | 26.584% (2025 - 2035) |
| REPORT COVERAGE | Revenue Forecast, Competitive Landscape, Growth Factors, and Trends |
| BASE YEAR | 2024 |
| MARKET FORECAST PERIOD | 2025 - 2035 |
| HISTORICAL DATA | 2019 - 2024 |
| MARKET FORECAST UNITS | USD Million |
| KEY COMPANIES PROFILED | Novartis, Intercept Pharmaceuticals, Guangzhou Medicines Corporation, Mirum Pharmaceuticals, Wuxi AppTec, Genfit, Boehringer Ingelheim, Gilead Sciences, Eisai, Fosun Pharmaceutical, Zhejiang Huadong Medicine, Hua Medicine, Duke University, SAB Biotherapeutics |
| SEGMENTS COVERED | Type, End User |
| KEY MARKET OPPORTUNITIES | Increasing prevalence of NASH, Growing research funding in biomarkers, Emerging diagnostic technologies, Rising awareness of liver diseases, Expansion of personalized medicine approaches |
| KEY MARKET DYNAMICS | increasing prevalence of NASH, growing healthcare expenditure, advancements in biomarker technology, rising demand for early diagnosis, favorable government initiatives |
| COUNTRIES COVERED | China |
Frequently Asked Questions (FAQ) :
The market size of the China Non-Alcoholic Steatohepatitis Biomarkers Market is projected to be valued at 10.5 million USD in 2024.
The expected market size of the China Non-Alcoholic Steatohepatitis Biomarkers Market is anticipated to reach 140.4 million USD by 2035.
The expected CAGR for the China Non-Alcoholic Steatohepatitis Biomarkers Market from 2025 to 2035 is approximately 26.584%.
The market includes hepatic fibrosis biomarkers, serum biomarkers, oxidative stress biomarkers, apoptosis biomarkers, and others.
The market value for Hepatic Fibrosis Biomarkers is estimated at 2.1 million USD in 2024.
The expected market value for Serum Biomarkers is projected to be 46.0 million USD by 2035.
Key players in the market include Novartis, Intercept Pharmaceuticals, Guangzhou Medicines Corporation, Mirum Pharmaceuticals, and Wuxi AppTec.
The value of Oxidative Stress Biomarkers is estimated to be 2.2 million USD in 2024.
The market presents growth opportunities due to increasing prevalence of non-alcoholic steatohepatitis and advancements in biomarker research.
Challenges such as regulatory hurdles and high research costs may hinder the growth of the China Non-Alcoholic Steatohepatitis Biomarkers Market.
Leading companies partner with us for data-driven Insights.
Kindly complete the form below to receive a free sample of this Report
Assistant Manager He holds an experience of about 7+ years in market research and business consulting, working under the spectrum of life sciences and healthcare domains. rahul conceptualizes and implements a scalable business strategy and provides strategic leadership to the clients. his expertise lies in market estimation, competitive intelligence, pipeline analysis, customer assessment, etc. in addition to the above, his other responsibility includes strategic tracking of high growth markets & advising clients on the potential areas of focus they could direct their business initiatives
Get in Touch
© 2025 Market Research Future ® (Part of WantStats Reasearch And Media Pvt. Ltd.)
